Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis. Early phase trials in T2DM indicate that tirzepatide improves clinical outcomes beyond those achieved by a selective GLP...

Full description

Saved in:

Bibliographic Details
Published in:	JCI insight Vol. 5; no. 17
Main Authors:	Willard, Francis S., Douros, Jonathan D., Gabe, Maria B.N., Showalter, Aaron D., Wainscott, David B., Suter, Todd M., Capozzi, Megan E., van der Velden, Wijnand J.C., Stutsman, Cynthia, Cardona, Guemalli R., Urva, Shweta, Emmerson, Paul J., Holst, Jens J., D’Alessio, David A., Coghlan, Matthew P., Rosenkilde, Mette M., Campbell, Jonathan E., Sloop, Kyle W.
Format:	Journal Article
Language:	English
Published:	United States American Society for Clinical Investigation 03.09.2020 American Society for Clinical investigation
Subjects:	Agonists Animals Arrestin beta-Arrestin 1 - physiology Blood Glucose - metabolism Clinical trials Diabetes Diabetes mellitus (non-insulin dependent) Drug dosages Fatty liver Gastric Inhibitory Polypeptide - pharmacology GLP-1 receptor agonists Glucagon Glucagon-Like Peptide-1 Receptor - agonists Glucose Hypoglycemic Agents - pharmacology Insulin Insulin - metabolism Insulin secretion Internalization Islets of Langerhans - drug effects Islets of Langerhans - metabolism Islets of Langerhans - pathology Ligands Male Metabolism Mice Mice, Knockout Obesity Peptides Pharmacokinetics Pharmacology Receptors, Gastrointestinal Hormone - agonists Therapeutics Weight control Therapeutics Diabetes
ISSN:	2379-3708, 2379-3708
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!